Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Triple-Negative Breast Cancer2010 · 4,280 citations
2. 2The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor‐negative, invasive breast cancer: The California Cancer Registry, 1999–20042008 · 223 citations
3. 3Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence2007 · 5,229 citations
4. 4Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer2008 · 2,948 citations
5. 5Recent insights into the function of autophagy in cancer2016 · 816 citations